Manisha Shah

Manisha Shah, MD


Make an Appointment




Gujarati, Hindi, Spanish


I’m a medical oncologist specializing in treating patients with neuroendocrine, thyroid and adrenal cancers as well as paraganglioma/pheochromocytoma and pituitary tumors. Along with my research team, I focus on discovering targeted therapies for these malignancies through the use of phase I-II clinical trials. These trials often lead to national studies as we learn about the types of drugs and drug combinations that best treat these cancers. Additionally, we perform tests in tumor genetics, tumor imaging, pharmacokinetics and pharmacodynamics of study drugs. My biggest contribution in the last decade has been to design and conduct clinical trials using drugs that have now become standard of care for patients with advanced thyroid cancer as well as neuroendocrine cancers. In Sep 2017, I was elected as chair of the International Thyroid Oncology Group (ITOG).

I direct the Endocrine Medical Oncology team and serve as a member of the Experimental Therapeutics Program and Thyroid Cancer Unit at the OSUCCC – James. Additionally, I’m professor of Internal Medicine in the Division of Medical Oncology for The Ohio State University. I’ve published in the Journal of Clinical Investigation, Journal of Clinical Oncology, Journal of Immunology, Lancet, Nature Medicine and New England Journal of Medicine. I’m proud to have been named as a Best Doctor in America and an awardee of Business First’s Forty Under 40.

I feel very fortunate to be at The James. We love our patients! All our team members are passionate about what they do, and it’s been extremely rewarding working together to help our patients enjoy a better quality of life with positive outcomes.

Education and Background


N.H.L. Municipal Medical College

Ahmedabad, India,


Buffalo General Hospital

Buffalo, NY

Sheth K. M. School of Post Grad

Ahmedabad, India,



Roswell Park Cancer Institute

Buffalo, NY


Ohio State University Wexner Medical Center

Columbus, OH

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Medical Oncology

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Shah has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

Eisai, Inc.


Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.

Strosberg D, Schneider EB, Onesti J, Saunders N, Konda B, Shah M, Dillhoff M, Schmidt CR, Shirley LA

Ann Surg Oncol 25


Clinical Trials | Lead



Related Videos

Thyroid Cancer Research at The James is Leading to New Treatment Options
Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type